Goldman Sachs Lowers Price Target on Johnson & Johnson to $159 From $162
Johnson & Johnson Price Target Raised to $166.00/Share From $163.00 by Wells Fargo
Leerink Partners Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Announces Target Price $182
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $175
A Quick Look at Today's Ratings for Johnson & Johnson(JNJ.US), With a Forecast Between $166 to $215
Johnson & Johnson Is Maintained at Outperform by RBC Capital
Johnson & Johnson Analyst Ratings
Johnson & Johnson (JNJ) Receives a Buy From Cantor Fitzgerald
Bernstein Adjusts Price Target on Johnson & Johnson to $177 From $171, Maintains Market Perform Rating
Hold Rating for Johnson & Johnson Amid 2024 Growth Deceleration and 2025 Optimism
Stifel Raises Johnson & Johnson's Price Target to $170 From $160
DBS Maintains Johnson & Johnson(JNJ.US) With Hold Rating
Johnson & Johnson: Navigating Pharmaceutical Opportunities and Patent Challenges – A Hold Rating Analysis
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $169
Johnson & Johnson Analyst Ratings
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $163
Leerink Partners Maintains Johnson & Johnson(JNJ.US) With Buy Rating
Johnson & Johnson Is Maintained at Outperform by RBC Capital
Johnson & Johnson Analyst Ratings
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $178